In our study, 3 of the 7 EGFR alteration cases are 19 exon deletion, which is recognized as a sensitive variant to EGFR tyrosinase inhibitor in lung cancer with 74% to 81% ORR[23]; Meanwhile, 4 of the 5 HER2 alteration cases are amplification, which can benefit from trastuzumab plus chemotherapy in breast, gastric, and other cancers.[24–28] Therefore, anti-EGFR or anti-HER2 targeted therapy may become alternative treatments for those OC patients with activated EGFR or HER2 variants after the failure of standard regimens. This evidence concerns the gene ERBB2 and lung carcinoma.